SHANGHAI – In 2011 Shanghai-based Hua Medicine Ltd. made headlines in China as a start-up R&D biotech flush with a $50 million commitment from venture capital investors and a crew of talented veterans as founders and board members.
SHANGHAI – Advaxis Inc. signed an exclusive licensing agreement with newly minted Global Biopharma Inc. (GBP), of Taiwan, to develop and commercialize ADXH-HPV, an immunotherapy treatment for human papillomavirus (HPV) associated diseases.
SHANGHAI – Amgen Inc. entered China in 2012, more than a decade after most other global players in the industry. While some may think the big biotech is a late comer, company execs say the time is just right to develop innovative drugs in a country where most drug makers focus on generics.
SHANGHAI – After a flurry of high-level meetings discussing China’s drug pricing, the new leadership said it will continue to apply pressure on drug prices to reduce the cost of healthcare, but will make greater use of market forces.
SHANGHAI – Few people are as well placed to understand the financing situation of China’s biomedicine sector than Mike Braun, managing partner for Deloitte’s Life Science & Health Financial Advisory Services in China.
BEIJING – At the recent China Trials: Global Clinical Trial Summit here, a confab of chief scientists and contract research organization (CRO) leaders declared that China needs to be elevated and considered much earlier in global trials design.
BEIJING – Friedhelm Blobel, CEO and president of Sciclone, knows about running a specialty pharmaceutical company in China. His company, based in Foster City, Calif., and listed on Nasdaq, has a 17-year track record in China selling its $100 million-a-year drug Zadaxin.
SHANGHAI – The growth of China’s biotech industry may be a more effective channel for talent than any of the myriad government programs to reverse the country’s ongoing brain drain.
BEIJING – Friedhelm Blobel, CEO and president of Sciclone, knows about running a specialty pharmaceutical company in China. His company, based in Foster City, Calif., and listed on Nasdaq, has a 17-year track record in China selling its $100 million-a-year drug Zadaxin.
